The management of relapsed CLL is an evolving field that currently defies a clear consensus. Combination chemo-immunotherapy produces the best response rates, 2, 8 yet the optimal regimen should be tailored for individual circumstances. The aims and selection of treatment are dependent upon several clinical factors. Age, performance status, previous treatments, the extent and duration of response to such treatments, and time from last treatment appear critical. In addition, the goal of therapy, whether aggressive or palliative, should be established. There is no evidence to date that any available chemo-immunotherapy combination is curative and patients invariably relapse again and subsequently develop resistance to chemotherapy, often with the loss of function of p53. 9 When refractory to purine analogues the median survival has been reported as < 1 year. 10 The humanized anti-CD52 monoclonal antibody alemtuzumab is approved for treating fludarabine-refractory CLL. In the pivotal study of alemtuzumab in 93 such patients, the overall response rate was 33%, though only 2% of patients achieved complete response (CR). 11 The median time to progression for responders was 9.5 months and there was an improvement in survival in responding patients at 32 months, compared with 16 months for all patients. Of note, alemtuzumab appears to have activity against cases that are unresponsive to chemotherapy because of the presence of p53 mutations. 12, 13 Despite often affecting hematologic responses, alemtuzumab has relatively poor activity against bulky lymphadenopathy. Alemtuzumab has shown benefit when used in combination with fludarabine. 14, 15 Studies are also examining the role of alemtuzumab treatment after chemotherapy to clear residual disease, 16 and this may be an effective way to obtain autologous peripheral blood stem cells free of contamination with CLL. 17 
Role of Transplantation in Chronic Lymphocytic Leukemia
Several studies have attempted to ascertain whether SCT might offer the potential of cure or reversal of chemotherapy resistance in CLL. Largely a disease of later life, with a median age of presentation between 65 and 70 years, most patients with CLL are insufficiently robust to consider such an approach with its attendant morbidity and mortality. However, 40% of patients with CLL are aged under 60 years and 12% under 50 years at the time of diagnosis. Younger patients do not have a worse prognosis than older patients and have similar prognostic factors. Unlike older patients, who often die of comorbidity not associated with the CLL, more than 90% of younger patients die because of CLL itself. 18 As such, this group might gain the most benefit and suffer the least morbidity and mortality from more aggressive approaches incorporating SCT. The various strategies for using SCT in CLL are explored herein.
Autologous Stem Cell Transplantation
There has been no prospective study directly comparing the outcome after conventional therapy compared with that obtained after autologous SCT, although a retrospective matched-pair analysis suggested a survival advantage for autologous SCT. 19 A number of phase II studies have reported the outcome following autologous SCT for CLL (Table 1) . [20] [21] [22] [23] [24] [25] [26] The approach is feasible in CLL with a transplantation-related mortality of between 2% and 10%. 25, 26 Encouraging early results were reported in patients with chemosensitive disease, 20 whereas patients transplanted in relapse or with chemoresistant disease had poor outcome. 21 Poor results with a high relapse rate after autologous SCT in CLL were also observed in a study of 16 patients. At a median follow-up of 41 months, 8 had relapsed and 6 had died (3 from progressive CLL). 24 Other groups have observed better results. In 18 patients with CLL including early-stage disease, transplantation was performed in 13 patients, only one of whom had relapsed at the time of publication. 23 Eight heavily pretreated patients received autologous SCT with partially purged CD34+ peripheral blood stem cells and though 4 patients remained in CR, the median follow-up was only 9 months. 22 The experience in Finland has been updated recently for 72 patients autografted in 5 centers between 1995 and 2005. 27 The median age was 57 years (range, 38-69 years) with a median time from diagnosis of 32 months (range, 6-181 months). The median number of previous therapies was 1. The most commonly used conditioning regimen was total body irradiation (TBI) 26 Jantunen et al 2006 27 Milligan et al 2005 25 Pavletic et al 1998 24 Dreger et al 1998 23 Khouri et al 1994 21 Sutton et al 1998 65 Itala et al 1997 22 Phase II Study Outcomes Following Autologous Stem Cell Transplantation for CLL Table 1 Abbreviations: AML = acute myelogenous leukemia; CLL = chronic lymphocytic leukemia; CR = complete remission; MDS = myelodysplastic syndromes; TRM = transplantation-related mortality and cyclophosphamide (Cy; n = 38, 53%). There were no early TRMs. Thirty-seven percent had relapsed or progressed after a median follow-up of 28 months. The projected median progression-free survival (PFS) and overall survival (OS) was 48 months and 95 months, respectively.
A pilot study from the Medical Research Council (MRC) enrolled previously untreated patients and followed them prospectively to assess the feasibility of performing autologous SCTs. 25 Only 65 of 115 patients (56%) entered into the study were able to proceed to autologous SCT following remission induction with fludarabine. However, only 1 patient died of early transplantation-related complications and the CR rate after transplantation was 74% (48 of 65). The 5-year OS was 77.5% and 5-year PFS was 51.5%. None of the variables examined at study entry were predictive of either OS or PFS. Sixteen of 20 patients available for analysis achieved a molecular CR in the first 6 months after transplantation. Detectable molecular disease by polymerase chain reaction (PCR) was highly predictive of disease recurrence. Of concern, 5 of 65 (8%) patients developed posttransplantation acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS). This equates to a 5-year actuarial risk of developing MDS/AML post autologous SCT of 12.4% (95% CI 2.5%-24%). No potential risk factor analyzed was predictive. The group postulates that potential causative factors might be fludarabine, low cell dose, and use of TBI in the conditioning regimen. This finding has been supported by the long-term outcome reported in a series from the Dana-Farber Cancer Institute, which reported an actuarial incidence of MDS/ AML in CLL patients postautograft of 12% at 8 years. 26 Although the early TRM is low after autologous SCT, there is a high incidence of opportunistic infections in patients with CLL compared with other patient populations. Whether this is due to disease-related immune defects in patients with CLL, or is secondary to the immune-suppressive effects of treatment is unknown. Patients have a better outcome when they are treated early in the course of the disease and when they have less tumor burden. By extrapolation of this principle, it might be considered beneficial to transplant selected high-risk patients in first complete or partial remission, though data sufficient to support this is lacking. One difficulty in selecting high-risk patients is that these patients might also have an adverse outcome even after SCT. The immunoglobulin gene mutation status maintains its poor prognostic significance after autologous transplantation 28 though it appears that this can be overcome using allogeneic SCT. 29, 30 A randomized trial proposed by the European Bone Marrow Transplant Group should help to address this issue. The timing of the harvesting of the cells and whether they should be harvested in first remission and kept until later in the treatment course also needs to be further investigated. It is not always possible to collect enough CD34+ cells, especially in heavily pretreated patients 31 and an interval of at least 3 months should be allowed between the last dose of fludarabine and stem cell collection. 32 The major problem after autologous SCT remains relapse of disease, and patients continue to relapse years later. 33 A number of methods including multiparameter flow cytometry analysis 34 and PCR 35 are being used to investigate whether persistence of minimal residual disease will predict which patients will relapse following transplantation in CLL. Molecular remissions can be achieved in more than two thirds of patients but these are not durable 25, [35] [36] [37] and most patients who achieve CR postautologous SCT will eventually relapse. Detectable molecular disease post transplantation is, however, highly predictive of clinical recurrence. 25 One of the major concerns in autologous transplantation is that reinfusion of tumor cells may theoretically contribute to the risk of relapse. Numerous groups have attempted to improve outcome by "purging" the graft. The techniques most frequently employed use either negative selection using B-cell monoclonal antibodies to deplete tumor cells from the graft or positive selection of stem cells using CD34 antibodies. Unfortunately these methods remain inefficient at removing CLL cells. 35 Purging also results in stem cell loss. If there has been difficulty in obtaining a sufficiently large harvest, as seen in 50% of cases in the MRC Pilot Study, purging cannot be performed. This problem could be addressed by attempting in vivo purging using alemtuzumab or rituximab as part of the conditioning regimen. In this way, high-dose alemtuzumab was used in one arm of the CLL3 trial from the German CLL Study Group, with unexpected consequences. 38 Sixteen patients were treated in this arm and received a median dose of alemtuzumab of 103 mg. A high incidence of initially unexplained skin rashes led to further analysis. Twelve of 16 patients (87%) developed a skin rash between 43 and 601 days post autologous SCT, in 7 of whom a diagnosis of graftversus-host disease (GVHD) could be made compared with no cases in the TBI/Cy only-conditioned patients. Autologous GVHD is an autoimmune syndrome initiated by autologous effector T cells that recognize self MHC Class II antigens and is usually self-limiting. In this case, however, all cases required immunosuppression and the median duration was 517 days (range, 60-867 days). The trial was discontinued because of the high nonrelapse mortality. However, of note, the addition of alemtuzumab led to improved disease control at the molecular level. It is interesting that the use of alemtuzumab in combination with other immunosuppressants before allogeneic SCT results in effective prevention of GVHD. In this situation it was postulated that the markedly immunosuppressive regimen depleted regulatory CD4 and CD8 T cells and natural killer cells, allowing subsequent development of autoimmune disease. The patients receiving alemtuzumab/TBI/Cy had a severe CD8 lymphopenia in the first year after SCT. The authors recommend that future trials investigating in vivo purging with alemtuzumab should use a less immunosuppressive conditioning regimen such as BEAM, and avoid the use of TBI.
The concept of using alemtuzumab for in vivo purging should perhaps not yet be discarded. When used at a modification from the standard doses (10 mg subcutaneously 3 times per week for 6 weeks) in 34 patients who had had a clinical response to a fludarabine-based regimen the CR rate improved from 35% to 79.5% with 56% achieving eradication of MRD. 39 Peripheral blood stem cell (PBSC) collection was subsequently successfully performed in 92%. Eighteen patients underwent autologous SCT with 17 remaining in CR at a median follow-up of 14.5 months post-SCT.
As induction regimens have evolved, it would now be useful to look at the new chemo-immunotherapeutic regimens in direct comparison with autologous SCT. 
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Myeloablative Allogeneic Stem Cell Transplantation
Myeloablative allogeneic SCT attempts to supplement the dose intensification effect of autologous SCT with alloreactive immune mechanisms to generate a GVL effect. This introduces the potential for better disease control, and possibly cure, but at the price of greater toxicity. The morbidity and mortality of allogeneic SCT mostly relate to organ failure caused by both the toxicities of the conditioning regimen, and acute GVHD (aGVHD) and chronic GVHD (cGVHD). The risk of life-threatening infection is increased by both GVHD itself and the immune-suppressive treatment used to control GVHD.
The feasibility of allogeneic SCT in CLL was first demonstrated in 1988 in 8 patients, 5 of whom were alive in CR after a median follow-up of 27 months post-SCT. 40 The high TRM rate was apparent from registry data with rates of 46%-50% reported. 41 Despite the high TRM, patients who survive can have long-term disease control (Table 2) . 20, [41] [42] [43] [44] Among 25 patients with CLL who underwent allogeneic SCT at the Fred Hutchinson Cancer Center, 44 14 developed grades 2-4 aGVHD and 10 developed extensive cGVHD. Nonrelapse mortality at day 100 was unacceptably high at 57% for the 7 patients conditioned with busulphan and cyclophosphamide and 17% for the 18 patients conditioned with TBI-containing regimens. Actuarial survival at 5 years for the 25 patients was 32%. All patients who received busulphan and cyclophosphamide died within 3 years of transplantation. For the 14 patients who underwent transplantation since 1992 and who received TBI, actuarial 5-year OS is 56%, suggesting that long-term disease-free survival might be achieved in this disease.
However, there are no data from randomized trials demonstrating improved outcome with dose intensification. Indeed, the major advantage of the use of allogeneic SCT appears to be the potential for a GVL effect. A strong GVL effect was noted with those developing acute or chronic GVHD having near complete protection from relapse. 45 This effect can be exploited by infusion of donor lymphocytes following allografting, 26, 46 or after cessation of immunosuppressive therapy. 47 Studies are under way addressing the issue of the number of lymphocytes required and the optimal timing of donor lymphocyte infusions after allogeneic SCT in this and other hematologic malignancies.
As HLA-matched sibling allogeneic transplantations are only possible in a quarter of all potential recipients, the use of unrelated donor stem cells has been investigated. Among 38 heavily pretreated patients, 11 were alive and disease free at a median of 6 years. 48 The 5-year overall survival rate was 33%, TRM was 38%, and disease-progression rate was 32%. Of note, 45% developed grade 2-4 aGVHD and 85% had cGVHD. The authors concluded that lasting remissions could be achieved but that the high TRM illustrated that HLA-mismatched unrelated donors should be avoided.
Comparison of Autologous Versus Allogeneic Stem Cell Transplantation
Registry data has suggested that though durable responses were being achieved after allogeneic SCT, survival was worse than after autologous SCT with 3-year probability of survival reported as 45% for allogeneic SCT and 87% for autologous SCT. 49 Studies from the M. D. Anderson Cancer Center, however, have suggested improved outcome after allogeneic compared with autologous transplantation. 21 In 15 patients with CLL refractory to or relapsed after chemotherapy with fludarabine, 13 (87%) achieved a CR posttransplantation. At the time of reporting, 9 patients (53%) remained alive and in CR with a median follow-up of 36 months, 50 suggesting that allogeneic hematopoietic transplantation can induce durable remission even in patients with CLL refractory to fludarabine. There are no studies directly comparing the outcome of autologous compared with allogeneic SCT. In a phase II study at Dana-Farber Cancer Institute, 162 patients with high-risk CLL were enrolled in a study between 1989 and 1999 in which 25 patients with an HLA-matched sibling donor underwent T-cell-depleted allogeneic transplantation and 137 with no sibling donor underwent B-cell-purged autologous transplantation. 26 The 100-day mortality was 4% in both autologous and allogeneic SCT groups, though later TRM had a major effect on outcome. With a median follow-up of 6.5 years there was no difference in OS of 58% after auto and 55% after allogeneic SCT. Progressionfree survival was significantly longer following autologous SCT than T-cell-depleted allogeneic SCT, but no significant differences were observed in disease recurrence or deaths without recurrence according to type of transplantation.
Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation
The rationale of reduced-intensity conditioning (RIC) allogeneic SCT is to exploit the GVL effect while avoiding the significant 41 Gribben et al 2005 26 Doney et al 2002 44 Pavletic et al 2000 43 Khouri et al 1997 50 Table 2 Abbreviations: CLL = chronic lymphocytic leukemia; CR = complete remission; GVHD = graft-versus-host disease; DLI = donor lymphocyte infusion; TRM = transplantation-related mortality morbidity and mortality associated with myeloablative conditioning. Indeed, study data indicates that RIC regimens do appear to be associated with a decreased mortality, and allow transplantation in older patients, making this approach more applicable to increased numbers of patients with CLL. [51] [52] [53] [54] [55] [56] [57] Patients in these studies were often heavily pretreated and refractory to therapy. Despite this the majority demonstrated donor engraftment with a high CR rate. Survival was improved in patients who underwent transplantation while they still had chemosensitive disease. These studies provide strong evidence for a clinically significant GVL effect in CLL. A major focus of ongoing research is the amount of pretransplantation and posttransplantation immunosuppression required to establish stable mixed chimerism and eventual full donor chimerism following RIC allogeneic SCT. The optimal patient selection, timing, and conditioning regimen for such RIC approaches to SCT remain to be elucidated, and these procedures continue to be investigational in nature. Although the acute morbidity and mortality appears significantly lower compared with high-dose conditioning regimens with allogeneic transplantation, the longer-term results are awaited. Benefit could potentially be gained by separating the beneficial GVL effects of allogeneic SCT from the detrimental ones of GVHD. One such approach would be to target tumor-specific antigens, and exvivo expansion of FACS-sorted donor-derived T-lymphocytes has allowed the infusion of peptide-specific cells with the potential to target CLL cells directly. Such experimental approaches hold great interest when considering future allogeneic SCT strategies.
Long-Term Disease Control in Patients Who Survive Myeloablative Allogeneic Transplantation For CLL (Data Refer to Absolute Numbers)
To examine whether RIC decreases treatment-related mortality after allogeneic SCT for CLL, the outcome of 73 patients treated with RIC was compared with that of 82 matched patients from the European Bone Marrow Transplant Registry (EBMTR) database who had undergone standard myeloablative conditioning for CLL during the same time period. 58 Patients undergoing RIC had a significant reduction of TRM, but a higher incidence of relapse. There was no significant difference in OS or event-free survival between the two groups.
Outcomes have been reported after RIC allogeneic SCT for 64 patients with advanced CLL using the Fred Hutchinson Cancer Research Center multi-institutional protocol using related (n = 44) or unrelated donors (n = 20). 59 As shown in Table 3 , the median age was 56 years (range, 44-69 years). The majority of patients were fludarabine refractory. TRM at 100 days was 11%, and 22% by 2 years, with significant GVHD. At a median follow-up of 5 years, 28 patients were alive, 21 in CR. Five-year OS was 48% and disease-free survival was 38%. Though complications were higher in the patients with unrelated donors, there were higher CR and lower relapse rates than with related SCT, suggesting more effective GVL activity from the unrelated donors. A similar high rate of GVHD was seen in a smaller group of Australian patients. 60 Clinical trials indicate that the incidence of GVHD can be reduced by the use of alemtuzumab. Unfortunately, it also delays post-SCT immune reconstitution, increases the risk of infective complications and potentially impairs the GVL effect. This impaired antitumor response might necessitate the early use of donor lymphocyte infusions post-SCT. 61 A study by the British Society of Bone Marrow Transplantation (BSBMT) used alemtuzumab with fludarabine and melphalan as the conditioning regimen. 62 Fortyone consecutive patients were treated; 24 had HLA-matched sibling donors and 17 had unrelated volunteer donors (4 mismatched). The conditioning regimen had significant antitumor effects with 100% of patients with chemosensitive disease and 86% with chemorefractory disease attaining CR or partial response. The TRM rate was 26%, OS was 51%, and relapse risk 29% at 2 years. GVHD Outcomes Following Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation for CLL Table 3 a After DLI. rates were relatively low with aGVHD occurring in 17 (41%) and cGVHD in 13 (33%). The unexpectedly high TRM rate was due to a high incidence of fungal and viral infections. What emerged from this study was the clear adverse prognostic factor of fludarabine refractoriness. This group of patients had a 2-year OS of only 31%.
It has been demonstrated that patients with unmutated CLL who have undergone autologous SCT have a poor outcome. 19, 28 This adverse event can be overcome with the use of allogeneic SCT. 30 Among 50 patients who underwent SCT, 34 had unmutated immunoglobulin variable heavy chain genes (IgVH; 14 allogeneic SCT and 20 autologous SCT) and 16 had mutated IgVH genes (9 allogeneic SCT and 7 autologous SCT). There was no difference in CR rate between mode of transplantation and IgVH mutational status. After a median follow-up of 5 years, autologous SCT resulted in a significantly higher relapse rate than allogeneic SCT in both mutational groups. Thus the GVL effect of allogeneic SCT might overcome the negative effect on outcome of unmutated VH gene status on outcome. Myeloablative conditioning may not be required for this effect. In 30 patients with poor prognosis CLL (as defined by mutational status of VH genes and cytogenetic abnormalities 11q-, 17p-) who underwent RIC allogeneic SCT, OS, and event-free survival for the poor-prognosis group were 90% and 92%, respectively, and was not significantly different to that seen in the good-prognosis group. 63 
Conclusion
No clear guidelines exist describing which patients are candidates for autologous SCT. Autologous SCT offers a chance of lasting remissions with low TRM rates, yet it appears to not be curative, and all patients eventually relapse. Whether this still results in improvement in survival, as has been observed in randomized trials in other diseases such as multiple myeloma, remains to be determined. Furthermore, it is currently unclear if autologous SCT offers a superior survival advantage over the newer chemo-immunotherapeutic regimens. Autologous transplantation appears to not overcome the poor prognosis conferred by unmutated VH genes or poor-risk cytogenetic abnormalities. Allogeneic SCT should be considered in these patients. Myeloablative regimens currently offer no survival advantage over autologous procedures and therefore a RIC regimen might be the optimal approach to management.
In this regard, European Bone Marrow Transplant (EBMT) guidelines have been established outlining indications for allogeneic SCT in CLL. 64 The guidelines conclude that there is an evidence basis supporting the efficacy of allogeneic SCT in CLL and that this approach is indicated for selected high-risk patients. Precisely what factors are defined as high risk is not clearly stated, but patients with p53 deletions or mutations are considered candidates in first remission, and ongoing studies are assessing the effect of biomarkers including IgVH mutational status and cytogenetic abnormalities to identify patients at sufficiently high risk to merit consideration for transplantation in first remission. The consensus of the EBMT working group was that allogeneic SCT was recommended early in the disease course for young patients with CLL who fail to achieve CR or who progress within 12 months after purine analogues, and those who relapse within 24 months after having achieved a response with purine analogue-based combination therapy or autologous transplantation. It is clear that neither of these categories requires assessment of biologic risk factors. There is consensus that patients requiring treatment who have p53 abnormalities have sufficiently poor prognosis to merit transplantation in first response. Ongoing prospective clinical studies are required to determine the additional risk factors that identify patients at sufficiently high risk to merit use of allogeneic SCT in first CR.
Myeloablative allogeneic SCT is associated with increased morbidity and mortality and should be restricted to selected patients with very poor prognosis. Although no direct comparisons of myeloablative and RIC allogeneic SCT have been performed, given the older age of patients with CLL, it seems most reasonable to consider RIC transplantations as the approach of choice for the majority of patients with CLL being evaluated for allogeneic SCT. This should be considered early in the disease course to avoid development of refractory disease. The indications for these approaches are shown in Table 4 . However, the high risk of GVHD needs to be taken into account. The optimal immunosuppressive conditioning regimen that minimizes GVHD while maximizing GVL remains to be defined. Questions remain regarding appropriate patient selection for SCT, when to proceed, the use of autologous versus allogeneic SCT, use of nonmyeloablative regimens, and how to optimize the GVL effect.
Despite encouraging initial results, we are still in the position where the follow-up of most clinical trials is too short to assess whether SCT can cure CLL. Future approaches to the management of this disease must take into account the balance between the increased morbidity and mortality of SCT in CLL with the curative potential that these approaches may offer. In the absence of any other treatment modalities currently capable of improving survival, the treatment of choice for younger patients with poorrisk CLL may indeed be allogeneic or autologous SCT. Continued enrollment of appropriate patients into well-designed clinical trials is vital for further progress.
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